Application of Serum Tumor Markers Combined with Narrow-Band Imaging-Magnifying Endoscopy in the Differential Diagnosis of Benign and Malignant Early Gastrointestinal Tumors
SONG Yanhua, WANG Jianfeng
Department of Endoscopic Diagnosis and Treatment, Nanyang Central Hospital,Nanyang Henan 473001
Abstract:【Objective】 To investigate the value of serum tumor markers combined with narrow-band imaging-magnifying endoscopy (NBI-ME) in differentiating benign and malignant early gastrointestinal tumors. 【Methods】 A total of 216 patients who underwent endoscopic examination and treatment were enrolled. According to postoperative pathological results, 104 patients with malignant gastrointestinal tumors were assigned to the observation group, and 112 patients with benign lesions were assigned to the control group. General clinical data, serum tumor markers [carcinoembryonic antigen (CEA), tumor-specific growth factor (TSGF), carbohydrate antigen 19-9 (CA19-9), and alpha-fetoprotein (AFP)], and NBI-ME features were compared between the two groups. The lesion characteristics and diagnostic accuracy obtained by conventional white-light endoscopy and NBI-ME were compared. Receiver operating characteristic (ROC) curves were used to evaluate the diagnostic performance of the relevant indicators. 【Results】 Serum levels of CEA, TSGF, CA19-9, and AFP in the observation group were significantly higher than those in the control group. The proportions of discontinuous lesion borders, irregular surface microstructures, and irregular microvascular patterns in tumor tissues were significantly higher in the observation group than in the control group (P<0.05). The NBI-ME image scores were significantly higher than those of conventional white-light endoscopy (P<0.05). ROC analysis showed that the combination of serum tumor markers and NBI-ME had the highest diagnostic efficacy, with the accuracy, sensitivity, and specificity of 94.44%, 95.19%, and 93.75%, respectively. 【Conclusion】 The combined use of serum tumor markers and NBI-ME demonstrates a high positive detection rate in patients with early gastrointestinal tumors and it is worthy of clinical application.
宋艳华, 王建锋. 血清肿瘤标志物联合窄带成像-放大内镜在早期消化道肿瘤良恶性鉴别中的应用价值[J]. 医学临床研究, 2026, 43(4): 563-565.
SONG Yanhua, WANG Jianfeng. Application of Serum Tumor Markers Combined with Narrow-Band Imaging-Magnifying Endoscopy in the Differential Diagnosis of Benign and Malignant Early Gastrointestinal Tumors. JOURNAL OF CLINICAL RESEARCH, 2026, 43(4): 563-565.
[1] CHIU P W Y, UEDO N, SINGH R,et al. An Asian consensus on standards of diagnostic upper endoscopy for neoplasia[J].Gut,2019 ,68(2):186-197.
[2] XU Y W, CHEN H, HONG C Q,et al. Serum IGFBP-1 as a potential biomarker for diagnosis of early-stage upper gastrointestinal tumour[J].EBIOMedicine,2020,51:102566.
[3] DING J H, JIN Z, YANG X X,et al. Plasma membrane Ca2+-permeable channels and sodium/calcium exchangers in tumorigenesis and tumor development of the upper gastrointestinal tract[J].Cancer Lett,2020,475:14-21.
[4] 安敏,高振军. 白光内镜联合超声内镜检查术在早期胃癌诊断中的应用价值[J].中国内镜杂志,2023,29(7):67-72.
[5] 朱亚男,王军,王娟,等. 早期胃癌和上皮内瘤变在放大内镜窄带成像技术下的表现[J].中国内镜杂志,2024,30(7):56-62.
[6] YAO K S. Use of magnifying endoscopy with narrow-band imaging can change the clinical practice of screening endoscopy for early upper gastrointestinal neoplasia[J].Dig Endosc,2022,34(5):1010-1011.
[7] 曾繁昌,曾繁明. 消化道疾病血清CRP与肿瘤标志物的联合检测意义[J].数理医药学杂志,2017,30(2):201-202.
[8] 中国胃肠肿瘤外科联盟,中国抗癌协会胃癌专业委员会.中国胃肠肿瘤外科术后并发症诊断登记规范专家共识(2018版)[J].中国实用外科杂志,2018,38(6):589-595.
[9] 八尾建史.放大胃镜[M].杨爱明,姚方,译.北京:人民卫生出版社, 2015:79.
[10] 刘振鹏,邓宏炬,梁秀兰. 内镜窄带成像技术在早期胃癌及癌前病变中的应用进展[J].中国医药科学,2017,7(3):45-48.
[11] 程捷瑶,吴晰,杨爱明,等.白光内镜联合内镜超声对早期胃癌浸润深度的判断[J].中华消化内镜杂志,2021,38(5):384-389.
[12] LI C M, LI L Z, SHI J. Gastrointestinal endoscopy in early diagnosis and treatment of gastrointestinal tumors[J].Pak J Med Sci,2020, 36(2):203-207.
[13] NAIR B, KURIAKOSE A, BABY B,et al. Tumor-Specific Growth Factor (TSGF): a futuristic tumor biomarker in early diagnosis of cancer[J].Adv Pharm Bull,2023, 13(3):483-488.
[14] WANG J, ZHANG X, CHEN W,et al. Regulatory roles of long noncoding RNAs implicated in cancer hallmarks[J].Int J Cancer,2020, 146(4):906-916.